Human fetal bone marrow-derived mesenchymal stem cell (hfBM-MSC) (hfBM-MSC)

Human fetal bone marrow-derived mesenchymal stem cells (hfBM-MSCs) are multipotent progenitor cells harvested from fetal bone marrow tissues. Unlike adult MSCs, fetal-derived cells exhibit superior proliferative capacity, longer telomeres, and enhanced osteogenic potential, making them attractive candidates for regenerative medicine (PubMed: 21948253). These cells function primarily through the secretion of bioactive molecules that modulate the immune system and promote endogenous tissue repair (PubMed: 19144671). They have been investigated for the treatment of skeletal disorders like osteogenesis imperfecta and various inflammatory conditions (PubMed: 15047090). As a living cell therapy, they represent a therapeutic modality rather than a molecular target for drug binding. Their clinical application is governed by their ability to home to sites of injury and integrate into host tissues or provide trophic support (PubMed: 16223844). However, their use is associated with challenges including potential tumorigenicity and ethical considerations regarding the source of the cells (PubMed: 22385513).

Other names

hfBM-MSCFetal bone marrow mesenchymal stem cellHuman fetal mesenchymal stem cell

hfBM-MSCs function through paracrine signaling, secreting cytokines and growth factors that promote tissue repair, and through immunomodulation by suppressing pro-inflammatory immune cells (PubMed: 24594887).